LONDON – Ophthalmology specialist Oculis SA added a further CHF15.5 million (US$15.7 million) in an extension to its series B round, as it in-licensed LME-636, an anti-TNF-alpha product that has the potential to be the first topical antibody drug for treating inflammatory eye conditions.